Vaccine Safety: What the Evidence Base Actually Shows

Abstract

Vaccines are among the most studied medical interventions in history, and decades of post-market surveillance have produced a detailed picture of both their benefits and their genuine risks. Serious adverse events do occur but are rare, quantifiable, and consistently outweighed by the harms of the diseases they prevent. Understanding the actual evidence — including real but uncommon risks — is essential for informed policy and individual decision-making.

Background

Vaccine safety is monitored through multiple overlapping systems that distinguish vaccines from most medical products. In the United States, the Vaccine Adverse Event Reporting System (VAERS) collects passive reports of any adverse event following vaccination. The Vaccine Safety Datalink (VSD) links vaccination records to medical claims data from millions of patients, enabling active surveillance. The Clinical Immunization Safety Assessment (CISA) project investigates individual cases in depth. Internationally, the WHO's Global Vaccine Safety Initiative and national equivalents maintain similar systems.

This infrastructure means that vaccine adverse events — including rare ones — are caught and characterized more rapidly than adverse events from most drugs. The picture that emerges is consistent: vaccines prevent enormous amounts of disease and death, and they carry real but rare serious risks.

The Evidence

Vaccines prevent millions of deaths annually. A 2024 modeling study in The Lancet estimated that routine childhood immunization prevented 154 million deaths over the past 50 years, equivalent to 6 lives saved per minute over that period (Rodrigues et al., 2024). Smallpox was eradicated; polio is near eradication; measles mortality has fallen by 99% in countries with high vaccination coverage. These are not contested figures.

Serious adverse events exist but are quantifiably rare. The evidence supports specific known risks at documented rates. The MMR vaccine causes febrile seizures in approximately 1 in 3,000 doses and immune thrombocytopenic purpura (ITP) in approximately 1 in 40,000 doses. The rotavirus vaccine was associated with intussusception (bowel obstruction) at a rate of approximately 1–5 cases per 100,000 doses of the Rotarix vaccine — a rate low enough that benefits still outweighed risks in most settings (Tate et al., 2016, New England Journal of Medicine). The first-generation RotaShield vaccine was withdrawn in 1999 when intussusception risk proved higher. This withdrawal is itself evidence that the safety system works.

The alleged MMR-autism link has been thoroughly refuted. The 1998 Wakefield paper claiming a link between MMR vaccination and autism was fraudulent, retracted, and its author lost his medical license. Subsequent research — including a 2019 Danish cohort study of over 650,000 children — found no increased autism risk among MMR-vaccinated children (Hviid et al., 2019, Annals of Internal Medicine). Rates of autism diagnosis have continued to rise in countries regardless of vaccination practices, and in populations with low vaccination rates.

COVID-19 mRNA vaccines carried real but rare cardiac risks. Post-authorization surveillance identified myocarditis (heart inflammation) following mRNA COVID-19 vaccines, particularly in young males after the second dose. The rate was approximately 1–4 cases per 100,000 doses in this group (Witberg et al., 2021, NEJM). Most cases were mild and resolved without treatment. The risk from COVID-19 infection itself — including myocarditis and multi-system inflammatory syndrome — substantially exceeded the vaccine-related myocarditis risk across age groups. The Johnson & Johnson vaccine was associated with rare thrombosis with thrombocytopenia syndrome (TTS) at approximately 4 cases per million doses, leading to changes in clinical guidance.

VAERS data requires careful interpretation. VAERS accepts reports of any adverse event following vaccination, regardless of causation. Temporal association (event occurring after vaccination) does not establish causation. VAERS is a signal-detection system, not an adverse event rate calculator; rates require population-level denominator data that VAERS does not provide. Misuse of VAERS data to infer causation or estimate rates is a common source of vaccine safety misinformation.

Counterarguments

Long-term safety of new vaccine platforms is unknown. mRNA vaccine technology was deployed at unprecedented scale for COVID-19, and its long-term safety profile extends only a few years. This is a reasonable point — all novel medical interventions require time and continued surveillance. However, the mechanism of mRNA vaccines (transient protein expression, no integration into DNA) provides theoretical grounds for expecting adverse events to emerge early rather than years later, as has been observed.

Compensation systems acknowledge real harm. The National Childhood Vaccine Injury Act of 1986 created the Vaccine Injury Compensation Program (VICP) in the US, which has paid out approximately $5 billion to roughly 10,000 claimants since 1989. This is evidence that vaccines occasionally cause harm — a fact that public health messaging has sometimes inadequately acknowledged.

Individual risk-benefit calculations vary. For most healthy adults, vaccine benefits substantially outweigh risks. But individual circumstances — age, prior infection, underlying conditions — affect the calculation. The myocarditis finding prompted some countries to preferentially offer alternative COVID-19 vaccines to young males, reflecting an individualized approach to risk-benefit.

What We Can Conclude

Vaccines are not risk-free, and acknowledging that rare adverse events occur is consistent with strong evidence that vaccination benefits far exceed harms at population level. The evidence base for vaccine safety is more comprehensive than for most medical interventions, and known risks are monitored and acted upon — as the RotaShield and Johnson & Johnson cases illustrate. The MMR-autism claim, by contrast, has been definitively refuted by large, well-conducted studies. Informed decision-making requires access to accurate characterizations of both vaccine benefits and real, quantifiable risks.

References

• Rodrigues, C. M. C., Plotkin, S. A., & Orenstein, W. A. (2024). Vaccination: A milestone on the road to health equity. The Lancet, 403(10432), 1229–1238.
• Hviid, A., Hansen, J. V., Frisch, M., & Melbye, M. (2019). Measles, mumps, rubella vaccination and autism: A nationwide cohort study. Annals of Internal Medicine, 170(8), 513–520.
• Witberg, G., Barda, N., Hoss, S., et al. (2021). Myocarditis after Covid-19 vaccination in a large health care organization. New England Journal of Medicine, 385, 2132–2139.
• Tate, J. E., Mwenda, J. M., Armah, G., et al. (2016). Evaluation of intussusception after monovalent rotavirus vaccination in Africa. New England Journal of Medicine, 374(20), 1966–1975.
• Institute of Medicine. (2012). Adverse effects of vaccines: Evidence and causality. National Academies Press.